Cytokine signaling in macrophages: beyond JAK-STAT
CYTOMAC aims to identify cytokine-specific transcription factors in macrophages to improve targeted therapies for inflammatory diseases by leveraging genetic diversity in mouse models.
Projectdetails
Introduction
Dysregulated macrophage function underlies many inflammatory diseases. Cytokines, small secreted signaling molecules with immune-modulatory functions, shape the macrophage’s phenotype, thereby affecting disease states. Puzzlingly, many cytokines with opposing functions utilize highly similar JAK-STAT signaling cascades, leaving it unclear how cytokine-specific responses can occur.
Previous Work
In my previous work, I studied enhancer activation in mouse macrophages from genetically different strains. By studying genetic variation, I found that transcription factor (TF) motifs crucial for enhancer activation can be identified. I further developed the bioinformatic tool MAGGIE to study TF motif mutations in different strains of mice, which subsequently enabled me to discover a novel TF important for enhancer activation by the cytokine interleukin-4.
Hypothesis
Based on my findings, I hypothesize that cytokines require specific, yet unidentified TFs that cooperate with JAK-STAT signaling to mount cytokine-specific effects.
Project Overview
CYTOMAC aims to identify these cytokine-specific TFs downstream of JAK-STAT that direct appropriate cell responses. I will exploit the genetic variation across mouse strains and study enhancer activation in macrophages from these strains in response to different disease-related cytokines. Specifically, I will:
- Use genetic diversity between mouse strains to identify specific TFs regulating cytokine-specific responses.
- Target these novel TFs in mouse macrophages.
- Target these novel TFs in human macrophages.
- Translate my findings to human disease and inflammatory disease models.
Clinical Relevance
Inhibitors targeting JAK-STAT show high potential in clinically treating inflammatory diseases, including rheumatoid arthritis. However, as they affect generic pathways of many cytokines, they come with considerable side effects, limiting applicability. CYTOMAC will reveal novel, cytokine-specific TFs, which will aid in developing better tailored intervention strategies.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 1.500.000 |
Totale projectbegroting | € 1.500.000 |
Tijdlijn
Startdatum | 1-9-2023 |
Einddatum | 31-8-2028 |
Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- STICHTING AMSTERDAM UMCpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Negative Regulation of Inflammatory Responses Revealed with Camelid NanobodiesThe project aims to develop new cell biology tools to uncover intricate signaling networks that downregulate inflammation, focusing on the roles of NLRC3 and NLRX1 in controlling pro-inflammatory responses. | ERC Consolid... | € 1.997.828 | 2024 | Details |
Understanding the functional role of Immune-related Intercellular Signalling Networks during tissue Development and CancerThis project aims to uncover immune-related intercellular crosstalk in tissue development and cancer using single-cell RNA-sequencing and functional assays to identify novel therapeutic targets. | ERC Starting... | € 2.025.000 | 2022 | Details |
Illuminating the Dark MicroProteome in Innate ImmunityMicroIMMUNE aims to uncover the microproteome in innate immune cells using computational and synthetic biology to explore their functions and interactions, potentially revolutionizing immune response understanding. | ERC Starting... | € 1.500.000 | 2025 | Details |
Targeted Immunocytokines by CaGing and local ReleaseThis project aims to develop and evaluate a novel, locally activated innate immune therapy for cancer that minimizes systemic toxicity while enhancing treatment efficacy. | ERC Proof of... | € 150.000 | 2025 | Details |
Targeting mechanisms of Thrombo-inflammationThis project aims to elucidate the molecular mechanisms of thrombo-inflammation through the novel TF-IFNAR1 heterodimer, potentially leading to innovative diagnostics and therapies for related diseases. | ERC Advanced... | € 2.499.000 | 2024 | Details |
Negative Regulation of Inflammatory Responses Revealed with Camelid Nanobodies
The project aims to develop new cell biology tools to uncover intricate signaling networks that downregulate inflammation, focusing on the roles of NLRC3 and NLRX1 in controlling pro-inflammatory responses.
Understanding the functional role of Immune-related Intercellular Signalling Networks during tissue Development and Cancer
This project aims to uncover immune-related intercellular crosstalk in tissue development and cancer using single-cell RNA-sequencing and functional assays to identify novel therapeutic targets.
Illuminating the Dark MicroProteome in Innate Immunity
MicroIMMUNE aims to uncover the microproteome in innate immune cells using computational and synthetic biology to explore their functions and interactions, potentially revolutionizing immune response understanding.
Targeted Immunocytokines by CaGing and local Release
This project aims to develop and evaluate a novel, locally activated innate immune therapy for cancer that minimizes systemic toxicity while enhancing treatment efficacy.
Targeting mechanisms of Thrombo-inflammation
This project aims to elucidate the molecular mechanisms of thrombo-inflammation through the novel TF-IFNAR1 heterodimer, potentially leading to innovative diagnostics and therapies for related diseases.